Anifrolumab Monotherapy Cuts Hospitalizations to Zero in Cutaneous Lupus Cohort

The investigator-initiated trial divided adults with coexisting chronic cutaneous and systemic lupus into three arms: conventional immunosuppressants (n=46), anifrolumab plus immunosuppressants (n=13), and anifrolumab monotherapy (n=12). After 12 months, overall infection incidence was statistically similar across groups, yet the character of infections diverged sharply. Bacterial pneumonias and soft-tissue infections clustered almost exclusively in the immunosuppressant-only arm, while viral infections predominated when anifrolumab was used.

These patterns align with anifrolumab’s mechanism of blocking type-I interferon signaling, which impairs antiviral responses but spares neutrophil and macrophage function critical for bacterial clearance. Conventional agents such as mycophenolate blunt both pathways, producing the observed excess of severe bacterial events. The study’s predominantly discoid-lupus, female cohort limits generalizability, yet the absolute risk reductions (32.6% to 0% hospitalizations) exceed typical effect sizes seen in observational SLE cohorts.

Prior TULIP-1/2 RCTs established anifrolumab’s efficacy in systemic disease but excluded skin-dominant phenotypes; this real-world series supplies the first comparative safety signal for cutaneous use. Next, a multi-center prospective registry or pragmatic RCT is required to confirm whether monotherapy sustains skin clearance without excess viral morbidity over three years and to define optimal glucocorticoid-sparing strategies.